Lung Cancer

Balancing Innovation and Value in Cancer Care: Spotlight on Non–Small-Cell Lung Cancer Treatment

February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non–Small-Cell Lung Cancer Treatment - Lung Cancer

The rising cost of healthcare, including cancer care, is an established trend in the United States. In 2015, Americans spent $3.2 trillion (nearly $10,000 per person) on healthcare, including hospital inpatient and outpatient care, physicians’ services, and prescription drugs. The National Cancer Institute estimates that by 2020, the annual cost of healthcare for Americans with cancer will reach $156 billion; based on current trends, this means that cancer care will represent approximately 20% of the country’s annual healthcare expenditures. [ Read More ]

Adding Pembrolizumab to Chemotherapy as First-Line Treatment Significantly Improves Outcomes in Patients with Advanced NSCLC

Charles Bankhead

November 2016, Vol 7, No 10 - Lung Cancer

Copenhagen, Denmark—Immunotherapy for advanced non–small-cell lung cancer (NSCLC) took a step toward first-line indication as results from a randomized clinical trial showed that patients who received pembrolizumab (Keytruda) plus chemotherapy had a significantly higher response rate compared with patients who received chemotherapy alone, reported Corey J. Langer, MD, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, at the 2016 European Society for Medical Oncology (ESMO) Congress. The clinical trial results (KEYNOTE-021) were also published in Lancet Oncology, and are available online. [ Read More ]

Immunotherapy with Atezolizumab Outperforms Chemotherapy in Previously Treated NSCLC

Charles Bankhead

November 2016, Vol 7, No 10 - Lung Cancer

Copenhagen, Denmark—Immunotherapy competition in non–small-cell lung cancer (NSCLC) continued to heat up as atezolizumab (Tecentriq) improved overall survival (OS) versus docetaxel, according to results from the randomized, phase 3 OAK clinical trial reported at the 2016 European Society for Medical Oncology Congress by Fabrice Barlesi, MD, Professor of Medicine, Aix-Marseille University, France. [ Read More ]

Ceritinib, a Newer ALK Inhibitor, Improves Progression-Free Survival After Crizotinib Failure in NSCLC

Charles Bankhead

November 2016, Vol 7, No 10 - Lung Cancer

Copenhagen, Denmark—Patients with heavily pretreated ALK mutation and non–small-cell lung cancer (NSCLC) had significant improvement in progression-free survival (PFS) after receiving the next-generation ALK inhibitor ce­ritinib, according to results from the ASCEND-5 study reported at the 2016 European Society for Medical Oncology Congress by Giorgio Scagliotti, MD, Professor of Respiratory Medicine, University of Torino, Italy. [ Read More ]

Pembrolizumab Succeeds, Nivolumab Fails, as First-Line Therapy for Advanced NSCLC

Phoebe Starr

November 2016, Vol 7, No 10 - Lung Cancer

Copenhagen, Denmark—Patients with non–small-cell lung cancer (NSCLC) who lack targetable EGFR or ALK mutations typically receive platinum-based doublet chemotherapy as first-line therapy. Two phase 3 clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress compared immunotherapy and platinum-based chemotherapy as first-line treatment for ­patients with NSCLC. In KEYNOTE-024, pembrolizumab (Keytruda) was superior to chemotherapy in terms of progression-free survival (PFS) and overall survival (OS), whereas in CheckMate-026, nivolu­mab (Opdivo) failed to improve PFS compared with chemotherapy. [ Read More ]

Nivolumab plus Ipilimumab Combination Promotes Durable Responses in Advanced Lung Cancer

Wayne Kuznar

August 2016, Vol 7, No7, Special Issue: Payers’ Perspectives in Oncology - Lung Cancer

The combination of the checkpoint inhibitor nivolumab with the anti-CTLA (cytotoxic T-lymphocyte antigen)-4 ipilimumab results in durable responses in patients with advanced small-cell lung cancer (SCLC) or advanced non–small-cell lung cancer (NSCLC), according to the results of 2 separate clinical studies presented at ASCO 2016.

[ Read More ]

Alectinib Potential First-Line Treatment for NSCLC Associated with ALK Mutation

Wayne Kuznar

August 2016, Vol 7, No7, Special Issue: Payers’ Perspectives in Oncology - Lung Cancer

New data from an interim analysis of the head-to-head, open-­label, phase 3, Japanese study J-ALEX show that alectinib (Alecensa) significantly improved progression-free survival (PFS) compared with crizotinib (Xalkori) in the frontline setting, said Hiroshi Nokihara, MD, PhD, of the National Cancer Center Hospital, Tokyo, Japan.

[ Read More ]